Our observation that GTS-21 suppressed antigen-specific, antigen processing-dependent CD4+ T cell development while promoting antigen-specific, antigen processing-independent CD4+ T cell development suggests α7 nAChR agonists or antagonists could potentially be useful in the treatment of autoimmune diseases or cancers. Here, CHRNA7 is linked to autoimmune disease.